The FDA's Compounded GLP-1 Warning Letters: What Patients Should Know

Semaglutide and tirzepatide are GLP-1 medications. The FDA-approved versions are made by their manufacturers and carry an FDA label. Compounded versions are prepared by licensed compounding pharmacies for an individual patient on a provider's prescription. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they're sold. That is true of every compounded medication, from every pharmacy, prescribed by every clinic, including Peak Medical Wellness. It isn't a secret and it shouldn't be buried in fine print.

For how these medications work and what treatment costs, see our GLP-1 weight loss guide and our GLP-1 cost guide for Fort Collins.

Reading the letters, the FDA's objections fall into a few patterns:

• Implying FDA approval. Websites describing compounded products as coming from an “FDA-approved pharmacy,” or using FDA logos or language in ways that suggest the product itself was approved. No compounding pharmacy is “FDA-approved,” and no compounded drug is.
• Claiming equivalence. Presenting a compounded product as the same as, or comparable to, the approved medication. The FDA's position is that compounded products should not be presented as equivalent to approved treatments.
• Borrowing the evidence. Saying a compounded product contains “clinically studied” ingredients, which implies the clinical trials of the approved drug apply to a product those trials never tested.
• Marketing that sidesteps the approval process. Promoting compounded drugs to the general public as if they were an approved alternative rather than an individually prescribed one.

The acting head of the FDA's drug center said in June 2026 that compounded GLP-1 products have not been proven safe, effective or of consistent quality like FDA-approved drugs. That's the agency's view, stated plainly, and it's the backdrop for every letter.

They did not say compounding is illegal; it's a legal, regulated practice when done properly for an individual patient. They did not say every compounded GLP-1 product is unsafe. And they did not say patients must stop their medication. If you're on a compounded GLP-1 and doing well, the right response to the news is a conversation with your prescriber, not a sudden stop.

On April 30, 2026, the FDA proposed keeping semaglutide and tirzepatide off the list of substances that large “outsourcing” compounders (called 503B facilities) may use to make batches in advance. If that proposal is finalized, it would affect the mass-produced, pre-made supply, not the traditional patient-specific compounding that 503A pharmacies do on a prescription. It is a proposal, not a rule, and not a ban. What it means for you is a practical question to ask any provider: which kind of pharmacy prepares your medication, and what's the plan if that supply changes?

Most of the letters went to online sellers. That isn't a coincidence. When a medication is sold through a website with a questionnaire, there is often no in-person evaluation, no baseline labs, no one checking blood pressure or weight on a scale, and no scheduled follow-up with the person who prescribed it. The marketing has to do the work that a clinical relationship normally does, and that's where the claims get stretched.

In-person, provider-directed care works differently. At Peak Medical Wellness, weight-loss care starts with a visit and labs drawn in our office. A provider reviews your history and results, decides whether a GLP-1 medication fits you at all, and if one is prescribed, follows you with scheduled visits and repeat labs. If a compounded medication is part of your plan, your provider tells you it is compounded, tells you it is not FDA-approved, and explains the benefits, risks and alternatives, including FDA-approved options, before you decide. We don't say that to claim our compounded medications are better than anyone else's. Compounded is compounded. We say it because being told clearly is the standard every patient should expect. Our patient safety and compliance page spells out how prescribing and pharmacy fulfillment work here.

1. Is this medication FDA-approved, or compounded? If compounded, which licensed pharmacy prepares it, in which state is it licensed, and is it a patient-specific (503A) pharmacy or an outsourcing (503B) facility?
2. Will I be evaluated in person, and will labs be drawn before I start?
3. Who follows my care, how often, and how do I reach them if something goes wrong?
4. What are the FDA-approved alternatives, and why is a compounded option being suggested for me?
5. What does the pharmacy's label say about the ingredient, strength and beyond-use date?
6. What happens to my care if this medication becomes unavailable?

A provider who answers all six without flinching is one you can work with. One who can't answer the first is the kind the warning letters were written about.

Bring whatever you have: the pharmacy label, the dose you're on, how long you've been taking it, and any labs. Your provider will want baseline labs here regardless, so there's no need to stop before your visit. The dose and the medication may or may not change; that's a decision made with your results in front of you, not in advance.